AngioDynamics Stock Price, News & Analysis (NASDAQ:ANGO)

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANGO shares.
View ANGO analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1-year price objectives for AngioDynamics' shares. Their ANGO share price targets range from $12.00 to $20.00. On average, they anticipate the company's stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 141.3% from the stock's current price.
View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts.

AngioDynamics' stock was trading at $13.77 at the beginning of 2023. Since then, ANGO stock has decreased by 50.8% and is now trading at $6.77.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, January 4th 2024.
View our ANGO earnings forecast.

AngioDynamics, Inc. (NASDAQ:ANGO) released its quarterly earnings results on Wednesday, October, 4th. The medical instruments supplier reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.01. The medical instruments supplier earned $78.70 million during the quarter, compared to the consensus estimate of $77.70 million. AngioDynamics had a net margin of 1.92% and a negative trailing twelve-month return on equity of 1.18%. AngioDynamics's revenue was down 3.4% on a year-over-year basis. During the same period last year, the company posted ($0.06) EPS.

AngioDynamics updated its FY24 earnings guidance on Wednesday, October, 4th. The company provided earnings per share guidance of ($0.34)-($0.28) for the period, compared to the consensus estimate of ($0.32). The company issued revenue guidance of $328-333 million, compared to the consensus revenue estimate of $328.57 million.

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

AngioDynamics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (2.65%), Jacobs Levy Equity Management Inc. (1.79%), Paradigm Capital Management Inc. NY (1.48%), Tamarack Advisers LP (1.19%), Heartland Advisors Inc. (0.98%) and Northern Trust Corp (0.93%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends.

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.